A Phase 2 interventional study of Apremilast and Second-generation H1 antihistamine in Chronic Urticaria, Chronic Spontaneous Urticaria and Chronic Inducible Urticaria, sponsored by Rashid Latif Medical College. Enrolling by invitation at 1 site in Pakistan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Rashid Latif Medical College · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study evaluates whether adding oral apremilast, a phosphodiesterase-4 inhibitor, to second-generation H1 antihistamines improves disease activity and quality of life in adults with chronic urticaria that is not controlled by antihistamines alone. Patients who chose apremilast plus antihistamines were compared over 12 weeks with patients who continued antihistamines alone. Disease activity was measured with the weekly Urticaria Activity Score (UAS7), quality of life with the Dermatology Life Quality Index (DLQI), and adverse effects were recorded at every visit.
Chronic urticaria is a mast cell-driven skin disease with recurrent wheals, angioedema or both for more than 6 weeks. Many patients remain symptomatic on up-dosed second-generation H1 antihistamines, and second- and third-line options (omalizumab, cyclosporine) are costly or need laboratory monitoring. Apremilast is an oral phosphodiesterase-4 inhibitor approved for psoriasis, psoriatic arthritis and Behcet disease; PDE4 is expressed in mast cells, basophils and eosinophils.
Design: single-centre, open-label, non-randomised, parallel-group controlled trial at the Department of Dermatology, Arif Memorial Teaching Hospital, Rashid Latif Medical College, Lahore, Pakistan. Eighty-six patients were enrolled by non-probability consecutive sampling (43 per group). Sample size was calculated with 95% confidence and 80% power using an expected response of 76.92% with add-on therapy versus 48.08% with antihistamines alone.
Allocation: after counselling on cost, off-label use and expected adverse effects, patients who agreed to take apremilast formed the experimental group; the others formed the control group.
Intervention: apremilast titrated over 5 days from 10 mg to 30 mg twice daily and continued for 12 weeks, in addition to the patient's second-generation H1 antihistamine. Controls continued the antihistamine alone.
Assessments: UAS7 at baseline and weeks 2, 4, 8 and 12; DLQI and body weight at baseline and week 12; adverse effects, compliance and antihistamine requirement at each visit. Data were analysed in SPSS version 26 with the independent and paired t-tests and the chi-square or Fisher's exact test; p of 0.05 or less was considered significant.
199 studies on the registry are indexed under Chronic Urticaria; 51 are open to participants now.
This study's planned enrollment of 86 is close to the median of 80 across 149 interventional studies indexed under Chronic Urticaria.
Browse Chronic Urticaria studies →Rashid Latif Medical College is the lead sponsor of 14 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Apremilast titrated over 5 days from 10 mg to 30 mg orally twice daily and continued for 12 weeks, in addition to the patient's second-generation H1 antihistamine at standard or up to fourfold dose.
Drug: Apremilast · Drug: Second-generation H1 antihistamine
Second-generation H1 antihistamine at standard or up to fourfold dose for 12 weeks without apremilast.
Drug: Second-generation H1 antihistamine
Oral apremilast, 5-day titration (10 mg to 30 mg) then 30 mg twice daily for 12 weeks.
Also known as: Otezla
Oral second-generation H1 antihistamine at the licensed dose or up-dosed up to fourfold, continued throughout the 12-week study.
Change in weekly Urticaria Activity Score (UAS7) from baseline to week 12
UAS7 is the sum of daily wheal (0-3) and itch (0-3) scores over 7 days, range 0-42; higher scores mean more active disease. Change is compared between groups.
Time frame: Baseline and 12 weeks
Change in Dermatology Life Quality Index (DLQI) from baseline to week 12
DLQI is a 10-item questionnaire scored 0-30; higher scores mean greater impairment of quality of life.
Time frame: Baseline and 12 weeks
Proportion of patients with at least 50% reduction in UAS7
Treatment response defined as a fall of 50% or more from baseline UAS7.
Time frame: 12 weeks
Proportion of patients with well-controlled disease (UAS7 of 6 or less)
UAS7 of 0 to 6 at week 12.
Time frame: 12 weeks
UAS7 at follow-up visits
Mean UAS7 at each follow-up visit compared between groups.
Time frame: Weeks 2, 4, 8 and 12
Antihistamine requirement
Antihistamine dose at week 12 recorded as reduced, unchanged or increased compared with baseline.
Time frame: 12 weeks
Number of participants with adverse effects
Nausea, vomiting, diarrhoea, headache, abdominal discomfort, weight loss (3% or more of baseline weight), mood changes and other events recorded at each visit.
Time frame: Up to 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Oct 2026, 1 month after the start.
Of 31 phase 2 interventional studies under Chronic Urticaria, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 26. This study's planned 1 month is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast
Rashid Latif Medical College